SG11201509442RA - 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator - Google Patents

4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator

Info

Publication number
SG11201509442RA
SG11201509442RA SG11201509442RA SG11201509442RA SG11201509442RA SG 11201509442R A SG11201509442R A SG 11201509442RA SG 11201509442R A SG11201509442R A SG 11201509442RA SG 11201509442R A SG11201509442R A SG 11201509442RA SG 11201509442R A SG11201509442R A SG 11201509442RA
Authority
SG
Singapore
Prior art keywords
cyclopropylacetyl
benzenesulfonamide
pyrrol
chlorophenyl
alpha
Prior art date
Application number
SG11201509442RA
Other languages
English (en)
Inventor
Neelima Sinha
Navnath Popat Karche
Ajay Ramchandra Tilekar
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50981599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201509442R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of SG11201509442RA publication Critical patent/SG11201509442RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
SG11201509442RA 2013-06-03 2014-06-02 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator SG11201509442RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1937MU2013 2013-06-03
PCT/IB2014/061891 WO2014195848A1 (fr) 2013-06-03 2014-06-02 4-(5-(4-chlorophényl)-2-(2-cyclopropylacétyl)-1,4-diméthyl-1h-pyrrol-3-yl)benzène-sulfonamide à titre de modulateur du nachr alpha 7

Publications (1)

Publication Number Publication Date
SG11201509442RA true SG11201509442RA (en) 2015-12-30

Family

ID=50981599

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509442RA SG11201509442RA (en) 2013-06-03 2014-06-02 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator

Country Status (22)

Country Link
US (1) US9447037B2 (fr)
EP (1) EP3004054A1 (fr)
JP (1) JP2016520642A (fr)
CN (1) CN105263905A (fr)
AP (1) AP2015008884A0 (fr)
AR (1) AR096462A1 (fr)
AU (1) AU2014276436B2 (fr)
BR (1) BR112015030171A2 (fr)
CA (1) CA2912841A1 (fr)
CL (1) CL2015003515A1 (fr)
CR (1) CR20150646A (fr)
CU (1) CU20150168A7 (fr)
EA (1) EA201592247A1 (fr)
IL (1) IL242837A0 (fr)
MA (1) MA38697A1 (fr)
MX (1) MX2015016539A (fr)
PE (1) PE20160009A1 (fr)
PH (1) PH12015502676A1 (fr)
SG (1) SG11201509442RA (fr)
TW (1) TW201446243A (fr)
WO (1) WO2014195848A1 (fr)
ZA (1) ZA201600021B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3623371A1 (fr) 2014-12-16 2020-03-18 Axovant Sciences GmbH Composés amide de quinuclidine à substituants géminal en tant qu'agonistes des récepteurs nicotiniques de l'acétylcholine 7
WO2016201096A1 (fr) 2015-06-10 2016-12-15 Forum Pharmaceuticals, Inc. Composés d'aminobenzisoxazole en tant qu'agonistes des récepteurs de l'acétylcholine α7-nicotinique
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
DK3433234T3 (da) 2016-03-22 2022-01-03 Merck Sharp & Dohme Allosteriske modulatorer af nicotinacetylcholinreceptorer
US11382875B2 (en) * 2017-04-07 2022-07-12 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Methods and compositions for modulating β-amyloid/α7-nAChR interactions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1732883A1 (fr) 2004-03-29 2006-12-20 Neurosearch A/S Nouveaux dérivés d'urea et leur utilisation médicale
US20060142349A1 (en) 2004-12-23 2006-06-29 Pfizer Inc Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
US7750011B2 (en) 2005-02-15 2010-07-06 Neurosearch A/S Diazabicyclic aryl derivatives and their medical use
CA2617394C (fr) 2005-09-13 2014-06-03 Janssen Pharmaceutica N.V. Derives de thiazole substitues par 2-aniline-4-aryle
ATE455114T1 (de) 2006-02-16 2010-01-15 Neurosearch As Enantiomerenreine chinuclidinyloxy-pyridazine und ihre verwendung als nikotin-acetylcholin- rezeptorliganden
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
AU2007265116A1 (en) 2006-06-27 2008-01-03 Abbott Laboratories Pyrrole derivatives and their methods of use
TW200813000A (en) 2006-06-27 2008-03-16 Abbott Lab Thiazoline and oxazoline derivatives and their methods of use
CN101796034A (zh) 2007-08-08 2010-08-04 神经研究公司 用作烟碱型乙酰胆碱受体的调节剂的新颖的1,2,3-三唑衍生物
CN101815512B (zh) 2007-10-04 2013-04-24 弗·哈夫曼-拉罗切有限公司 环丙基芳基酰胺衍生物和其用途
CA2701214C (fr) 2007-10-04 2016-08-02 F. Hoffmann-La Roche Ag Derives d'arylamide substitue par tetrazole et leurs utilisations
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
ES2442932T3 (es) 2008-03-19 2014-02-14 Janssen Pharmaceutica N.V. 1,2,4-Triazoles trisustituidos como moduladores de receptores nicotínicos de acetilcolina
US7786171B2 (en) 2008-04-04 2010-08-31 Abbott Laboratories Amide derivatives as positive allosteric modulators and methods of use thereof
JP2011516599A (ja) 2008-04-17 2011-05-26 グラクソ グループ リミテッド ニコチン性アセチルコリン受容体サブタイプα７のモジュレーターとしてのインドール類
EA018187B1 (ru) 2008-05-09 2013-06-28 Янссен Фармацевтика Нв Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
US8563579B2 (en) 2009-01-15 2013-10-22 Anvyl Llc α-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
US20120071469A1 (en) 2009-05-14 2012-03-22 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
JO3078B1 (ar) 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
JP5865397B2 (ja) 2011-02-03 2016-02-17 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ α７ｎＡＣｈＲのモジュレータとして使用されるピロール誘導体
LT2678327T (lt) * 2011-02-23 2016-11-25 Lupin Limited Heteroarilo dariniai kaip nachr alpha7 moduliatoriai
SG193387A1 (en) 2011-03-31 2013-10-30 Lupin Ltd Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease
US8946432B2 (en) * 2011-07-05 2015-02-03 Lupin Limited Biaryl derivatives as nAChR modulators
WO2013132380A1 (fr) 2012-03-06 2013-09-12 Lupin Limited Dérivés de thiazole en tant que modulateurs de nachr alpha 7
EP2945936A1 (fr) 2012-11-12 2015-11-25 Lupin Limited Dérivés de thiazole en tant que modulateurs de nachr alpha-7
EP2945941B1 (fr) 2013-01-16 2016-12-07 Lupin Limited Dérivés de pyrrole en tant que modulateurs d'alpha-7-nachr
EP2970180A1 (fr) 2013-03-13 2016-01-20 Lupin Limited Dérivés de pyrrole utilisés comme modulateurs des récepteurs nicotiniques à l'acétylcholine (nachr) alpha-7

Also Published As

Publication number Publication date
CR20150646A (es) 2016-04-07
CN105263905A (zh) 2016-01-20
WO2014195848A1 (fr) 2014-12-11
IL242837A0 (en) 2016-02-01
BR112015030171A2 (pt) 2017-07-25
MX2015016539A (es) 2016-04-15
JP2016520642A (ja) 2016-07-14
AP2015008884A0 (en) 2015-11-30
TW201446243A (zh) 2014-12-16
EP3004054A1 (fr) 2016-04-13
CU20150168A7 (es) 2016-06-29
AU2014276436A1 (en) 2015-12-17
MA38697A1 (fr) 2017-03-31
AU2014276436B2 (en) 2017-03-02
US20160107990A1 (en) 2016-04-21
US9447037B2 (en) 2016-09-20
EA201592247A1 (ru) 2016-04-29
CL2015003515A1 (es) 2016-07-01
CA2912841A1 (fr) 2014-12-11
ZA201600021B (en) 2017-05-31
PE20160009A1 (es) 2016-02-14
PH12015502676A1 (en) 2016-03-07
AR096462A1 (es) 2015-12-30

Similar Documents

Publication Publication Date Title
IL248350B (en) Fast-acting insulin preparations
LT3233108T (lt) Greitai veikiančios insulino kompozicijos
ZA201800511B (en) Rapid-acting insulin compositions
EP2963068A4 (fr) Composé polymérisable, composition polymérisable, polymère et corps optiquement anisotrope
IL259824B (en) History of 2-[3-(azolyl)phenyl]-3,1-thiazole-5-carboxylic acid for use as drugs
ZA201600021B (en) 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator
HK1218385A1 (zh) 作為 激酶調節劑的雜芳環化合物
EP3178859A4 (fr) Composition polymérisable, objet moulé et utilisation de ceux-ci
SG11201507352YA (en) Methods for purifying 5-(halomethyl)furfural
GB201616843D0 (en) Polymerizable composition comprising compound having mesogenic group, and polymer thereof
EP3194371A4 (fr) Composés d'imidazolium antimicrobiens
GB201805406D0 (en) Band-Fastened,Convenience-Packaging for storing absorbent personal care articles
SG11201608845PA (en) Cosmetic composition containing mentha haplocalyx as active ingredient
EP3505201A4 (fr) Emballage de seringue.
PL3231417T3 (pl) Odporna na składowanie kompozycja oftalmiczna
GB201616880D0 (en) Compound for use in medicine
SG10201609022RA (en) Secure file storage
EP3389795A4 (fr) Composition d'hygiène personnelle occlusive
TH170710B (th) สูตรตำรับต้านการกัดกร่อนที่มีเสถียรภาพการการเก็บรักษา
TH1401001431B (th) สูตรปูนหล่อแบบฟันป้องกันจุลชีพที่มีซีโอไลท์เป็นส่วนประกอบและชิ้นหล่อแบบฟัน จากสูตรดังกล่าว